ROTAPRO Rotational Atherectomy System
Boston Scientific Corp · Decision date Oct 20, 2026
What did the FDA decide?
The FDA record P900056/S228 shows an OK30 decision dated 2026-10-20 for a 30-Day Notice supplement to PMA P900056, submitted by Boston Scientific Corp for the ROTAPRO Rotational Atherectomy System, a coronary atherectomy catheter under product code MCX. The stated supplement reason is a process change involving the manufacturer, sterilizer, packager or supplier.
The source statement describes updates to the PCBA adhesive inspection process and the introduction of new adhesive dispensers for the device. Because this is a supplement to an existing PMA rather than a new approval of the whole system, the notice concerns manufacturing process details only, and the record does not describe the prior inspection method, dispenser specifications, validation data, or any safety or effectiveness findings.
Specific information absent from the supplied fields includes which manufacturing site is affected and what evidence supported the change.
FDA approval order statement
updates to the PCBA adhesive inspection process and introduction of new adhesive dispensers for the ROTAPRO Rotational Atherectomy System
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 20, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P900056/S228
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- MCX
- Decision code
- OK30
- Decision date
- Oct 20, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: CATHETER, CORONARY, ATHERECTOMY.
- Applicant
- Boston Scientific Corp
- Product code
- MCX
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P900056. Subsequent supplements may change the device or its indications.
FDA decision timeline
P900056 · Original PMA
ROTABLATOR(R)
P900056/S228 received
Application receipt date recorded by FDA.
P900056/S228 · FDA decision
30-Day Notice
P900056/S226 · Related supplement
ROTAPRO Rotational Atherectomy Systems
P900056/S229 · Related supplement
ROTAPRO Rotational Atherectomy System
Timeline entries are records held by MedtechLedger for P900056. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P900056
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ROTABLATOR(R)P900056 | Boston Scientific Corp | PMA approval | May 28, 1993 | FDA |
ROTAPRO Rotational Atherectomy SystemsP900056/S226 | Boston Scientific Corp | PMA supplement | Oct 21, 2026 | FDA |
ROTAPRO Rotational Atherectomy SystemP900056/S229 | Boston Scientific Corp | PMA supplement | Oct 21, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- Two Scimed Pl., Maple Grove, MN, 55311
Sources and methodology
- Original FDA record: P900056/S228
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

